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Significance: Biofilms have been implicated in a variety of wound complica-
tions.
Recent Advances: Research has confirmed that biofilms form in wounds of
patients experiencing delayed healing and may be a precursor to infection.
Critical Issues: Research into the strength of this association is still in its
infancy. Is biofilm formation a cause of these complications, a step toward
them, or a signal that unresolved factors injuring tissue or delaying healing
are setting the stage for biofilm formation, infection, and healing delay? To
qualify biofilms for use in informing clinical practice decisions, biofilm char-
acteristics supporting those decisions need standardized definitions and valid
evidence that they predict or diagnose healing or infection outcomes. Litera-
ture searches of relevant terms reviewed biofilm definitions and validation of
their role in predicting and diagnosing delayed wound healing or infection.
Future Directions: Further research is needed to provide a rapid accurate
technique to identify and characterize biofilms in ways that optimize their
validity in diagnosing or screening patient risk of infection or delayed healing
and to inform clinical decisions. This research will help validate biofilm’s ca-
pacity to support wound care clinical practice decisions and establish their
importance in guiding clinical practice.
SCOPE AND SIGNIFICANCE
Evidence indicates that bio-
films exist in a majority of chronic
wounds.1,2While developing evidence-
based wound infection guidelines, the
Association for the Advancement of
Wound Care Guideline Task Force
observed evidence gaps supporting
biofilm-based clinical decisions to di-
agnose, screen, or treat wounds at risk
of delayed healing or infection.3 There
is no point-of-care tool to confirm the
wound biofilm presence. Research to
date has focused primarily onmethods
to manage biofilm, while preclinical
research has examined its impact on
wound healing. Research needs to
clarify risk factors for biofilm forma-
tion and its impact on optimizing
management practices in nonhealing
and/or infected wounds.
TRANSLATIONAL RELEVANCE
Translational research4–6 has
shown that when biofilm is delib-
erately introduced into controlled
wound models in vivo, infection may
ensue, healing is delayed, and in-
terventions to remove wound bio-
film reverse this delay.7 In subjects
with comorbidities, wound healing
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has been observed to be delayed more so than in
wild-type subjects,8–10 suggesting interactions bet-
ween host factors and microbial bioburden. There-
fore, further translational research is needed to
ascertain what host–environment–organism inter-
actions are required for wound biofilms to develop
and compromise wound infection status and healing
progression.
CLINICAL RELEVANCE
Observation of biofilms in complex chronic
wounds is difficult, requiring a trained clinical eye if
visible11–13 and expensive, highly technical micro-
scopes if microscopic.1,2 However, biofilms can
readily be visualized on the surface of long-term
urinary catheters and this has been directly associ-
ated with an increased infection rate.14 Verifying
catheter biofilm as a primary source of urinary tract
infection relies on clinical signs of infection, direct
visual observations of catheter biofilm, and urine
analysis. Similarly, by better understanding the
clinical signs of wound biofilm15 and utilizing future
point-of-care tools to confirm wound biofilm, man-
agementpractices andpatient care canbe optimized.
BACKGROUND
Biofilm is defined as ‘‘a structured community of
microbial cells enclosed in a self-produced poly-
meric matrix that is adherent to an inert or living
surface.’’16 The role of biofilm as a precursor, a
signal, or a cause of delayed wound healing or
progressive infection interacting with host, envi-
ronment, or microbial variables (Fig. 1) needsmore
scientific and clinical clarification to provide full
support for evidence-based clinical practice to im-
prove wound outcomes. While it is accepted that
further translational research and clinical studies
designed to investigate factors and relationships
between biofilm presence and wound recalcitrance
are warranted, the current knowledge base is suf-
ficient to ensure that patients benefit from biofilm-
basedwoundmanagement practices in the interim.
Objective
To critically review the literature to determine
the clinical usefulness of wound biofilm in accu-
rately guiding decisions as well as identify the re-
search needed to improve infection and wound
healing outcomes.
DISCUSSION
Methods
Search and selection process: to assess the va-
lidity, reliability, and efficacy of wound biofilm in
guiding wound care decisions, authors searched
the MEDLINE, CINAHL, and Scopus literature
databases from 1966 to January 10, 2014, for arti-
cles containing the term ‘‘biofilm’’ combined with
the terms ‘‘wound infection’’ or ‘‘wound healing.’’
Additional searches combined the last two terms
with ‘‘sensitivity,’’ ‘‘specificity,’’ or ‘‘predict’’ to cap-
ture studies validating sensitivity or specificity of
biofilms in promoting delayed wound healing
or clinical infection or positive or negative predic-
tive validity used clinically on admission to practice
to identify individuals at risk of delayed healing
or infection. Abstracts were read and searched for
the terms ‘‘sensitivity,’’ ‘‘specificity,’’ ‘‘reliability,’’ or
‘‘predict.’’
Any study was included if it objectively docu-
mented wound biofilm’s reliability and/or validity
for predicting infection or diagnosing or predicting
documented delayed healing. Clinical signs and
symptoms were used to define the outcome ‘‘wound
infection’’ rather than a biopsy microbial burden
of ‡105 colony forming units. The latter is often
isolated from healing wounds without clinical infec-
tion signs (false-positive results) and often not iso-
lated fromearly clinical infections.17,18Consequently,
biopsy was not used as a standard for screening or
diagnosing clinically recognized wound infection.
This is important because false positives could result
in unnecessary antibiotic use placing patients at
future risk of harboring antibiotic-resistant strains
of organisms. Case reports, abstracts of meetings,
review articles, and non-English language arti-
cles were excluded as well as studies that did not
contain objective characterization of one or more
Figure 1. Biofilm in perspective of factors involved in delayed wound
healing.
296 HURLOW ET AL.
Fo
r R
ev
iew
 O
nly
 
No
t In
ten
de
d f
or 
Di
str
ibu
tio
n 
or 
Re
pro
du
cti
o
clinical signs of wound infection (increased pain,
heat, purulent exudate, odor, or swelling19) or un-
explained delayed healing for chronic wounds.
Results
A CONSORT diagram of biofilm evidence found
in the literature search is presented in Figure 2.
Definitions
The literature search found the following defi-
nitions of biofilm:
 Structured community of microbial cells en-
closed in a self-produced polymericmatrix that
is adherent to an inert or living surface.16
 A complex microbial community, consisting of
bacteria embedded in a protective matrix of
sugars and proteins, known to form on the
surface of medical devices and in wounds.20
 A coherent cluster of bacterial cells embedded
in a biopolymer matrix, which compared with
planktonic cells, shows increased tolerance to
antimicrobials and resists the antimicrobial
properties of the host defense.21
 Communities of bacteria attached to a sur-
face, embedded in a self-produced extracellu-
lar polysaccharide matrix.22
A composite operational definition of wound bio-
film consistent with currently available literature is:
communities of surface-attached or self-attached
microorganisms, embedded within a hydrated ma-
trix of extracellular polymeric substances (or slime),
which provides protection against antimicrobial
agents and host defenses.
State of the science
Biofilm and wound infection. Costerton first
described the link between biofilm and infections,22
and Hall-Stoodley et al. have recently revisited
diagnostic guidelines for biofilm-associated infec-
tions.23 Based on their clinical and scientific
observations in wounds, Bjarnsholt et al. hypothe-
sized that Pseudomonas aeruginosa biofilm is
prevalent in wound infections and is a causal factor
in wound chronicity, particularly deeper in the
wound bed.24 While this theory has been chal-
lenged by others who consider wound biofilm to be
problematic due to its multispecies nature—and
initially more surface-associated25—the notion that
biofilm can cause wound infections is generally
accepted.26 Host defenses are less effective against
biofilm bacteria than they are against planktonic
bacteria, and biofilm bacteria are more tolerant
to antiseptics and antibiotics than planktonic bac-
teria.27 The combination of compromised host
defenses, unresolved tissue damage, and the stub-
born tolerance of biofilm to external antimicrobial
agents places subjects with chronic wounds and
biofilm at particularly high infection risk. Biofilm
progression in local tissue is likely to be associated
with local inflammatory activity and theproduction
of microbial toxins that causes tissue damage28;
surface-associated biofilm may shed biofilm frag-
ments or planktonic cells that can seed adjacent
tissues and surfaces.47,48
Biofilm and wound healing. A growing body of
in vivo evidence now exists that implicates biofilm
in delayed wound healing.4 Various animal models
are providing insight into the ways in which bio-
films can delay healing. The multispecies biofilm
has been shown to be more pathogenic than single
species,29 and different species exhibit different
levels of biofilm virulence.30 Elgharably et al. pro-
vided the first direct evidence of biofilm involve-
ment in human deep sternal wound infection.49 It
has been demonstrated that biofilm impairs key
healing processes such as the inflammatory im-
mune response, granulation tissue formation, and
epithelialization.5 Biofilm has been shown to tol-
erate antibiotics and topical antiseptics in isola-
tion, although multimodal strategies to suppress
biofilm were more effective.7
Biofilm and moisture. While moisture is essen-
tial for optimal wound healing, poor moisture/ex-
udate control within a wound environment is likely
to encourage the development of biofilm.11,12 His-
torically, the appropriate use of moisture-retentive
dressings (e.g., hydrocolloids) has been shown to
significantly reduce the likelihood of infection and
healing time in randomized controlled trials com-
pared to gauze-dressed clinical acute31 and chronic
Figure 2. CONSORT diagram of MEDLINE, CINAHL, and Scopus biofilm
search results (number of citations found).
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wounds.32 Consequently, moisture balance is es-
sential to optimize the wound environment for
healing and minimize the opportunity for biofilms
to develop.
Diagnostic validity of wound biofilm
Three small studies explored diagnostic validity
of biofilm presence in mixed chronic wounds1,33 or
burns34 experiencing delayed healing. As may be
expected given the early stage of biofilm research,
no studies were found reporting reliability or pre-
dictive or validity of any aspect of biofilm develop-
ment for screening chronic or acute wounds likely
to (a) become infected or (b) experience delayed
healing (Fig. 3). A study by Wolcott and Rhoads re-
ported 77% of 190 subjects with critical limb ische-
mia (peri-ulcer TcPO2<20mmHg) healed during a
5-year trial after receiving at least five episodes of
biofilm-based wound care.35 This was reduced to
67% healed in the 79 subjects who followed the
Figure 3. Diagnostic validity of wound biofilm.1,33,34 Biofilm currently lacks
the positive and negative predictive validity to support clinical screening
decisions needed to improve wound healing or infection outcomes. To see
this illustration in color, the reader is referred to the web version of this
article at www.liebertpub.com/wound
Figure 4. Mindmap exploring the links betweenwound biofilm and factors that lead to its development and the effects it has on thewound and ultimately, the patient
quality of life. *See references 43 and 44. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/wound
298 HURLOW ET AL.
Fo
r R
ev
iew
 O
nly
 
No
t In
ten
de
d f
or 
Di
str
ibu
tio
n 
or 
Re
pro
du
cti
on
protocol with both diabetes and osteomy-
elitis, underscoring the importance of host
and wound environment variables, in ad-
dition to biofilm, in delaying healing.
Lessons learned
Wound biofilm has been documented as
emerging in acutewound drainswithin 2h
after surgery36 in damaged tendons37 and
in chronic1,2,33,34 and acute1,49 wounds.
However, there is still a need for further
evidence-based knowledge in improving
clinical wound or patient outcomes. In ad-
dition to urinary tract infection research,14
wound biofilm research may learn from
parallels of early research on catheter-
related bloodstream infections (CR-BSI),
which determined that biofilm formation
on catheters is a precursor of CR-BSI that
is established for longer than 10 days.38,39
Despite there being no method to detect
catheter biofilms, local and systemic signs
of infection40 are used in conjunction with
paired quantitative blood cultures to pro-
vide thehighest accuracy of biofilm-related
CR-BSI.41 Wound biofilm research may
benefit by following a similar trajectory in
the absence of a simple, rapid, reliable
biofilm detection method.
Detection of wound biofilm may em-
power wound care providers to avert in-
fection before its clinical signs manifest
such as elevated temperature, suppura-
tion, increasing wound pain, erythema
or edema, or unexplained healing delay.
Wounds that do not heal despite rigor-
ously applied standards of care may alert
healthcare providers to examine thewound
for direct or indirect signs of biofilm15 or
inert foreign matter such as sutures or
gauze fibers that may act as a biofilm sub-
strate.42 Healthcare providers may there-
fore use nonhealing, local temperature
elevation, or suspected low-grade inflam-
mation as indirect clinical indicators of
wound biofilm,15 thus informing care while
avoiding false positives leading to unnec-
essary antibiotic use. Future biofilm detec-
tion may enhance screening or diagnostic
validity or reliability of current tools that
alert clinicians to impending wound infec-
tion or healing delay.
A mind map has been considered to
explore the complex interrelated causes
of delayed healing and infection, and to
TAKE-HOME MESSAGES
What we know about wound biofilm
 Biofilms can form in chronic wounds1,2,33,34 and, less frequently, in acute
wounds.49
 Biofilm presence means that stubborn communities of microorganisms
are established that are tolerant to antibiotics, antiseptics, and inflam-
matory processes.
 Biofilm development has been shown to delay healing15 and can lead to
infection.26
 Addressing biofilm requires management of host and environmental
factors that led to their development (Fig. 4) as well as wound cleansing,
debridement, or antimicrobial use.
 Biofilm can be visualized using a variety of microscopy techniques, in-
cluding fluorescent staining with confocal microscopy and peptide nucleic
acid fluorescent in situ hybridization,2,45 scanning electron microscopy,1
and light microscopy in conjunction with gram staining.46
 There is growing evidence for how best to recognize biofilms in clinical
wounds based on wound recalcitrance, recurring infection, ineffective-
ness of antibiotics, and increasing or excessive wound fluid.11,12,15,50
 Diagnostic confirmation of the presence of biofilm in a wound will be
useful in supporting decisions that improve clinical outcomes in wounds
that do not appear to be healing normally, while conserving limited
clinical and economic resources.
 All local and underlying causes of delayed wound healing should be addressed
to reduce the likelihood of biofilm-related delayed wound healing or infection.
Opportunities for wound research on biofilms
 What do clinicians need to know about biofilm to improve wound care
outcomes?
 What is its importance in clinical wound management as a screening or
diagnostic tool or as a signal to address more rigorously the factors that
led to biofilm development?
 How can clinicians use biofilm information to improve patient and wound
outcomes beyond those obtained using currently available diagnostic or
screening tools?
 Under what circumstances is clinical biofilm development not likely to delay
healing or lead to infection? Knowing this may prevent unnecessary treatment.
 Point-of-care biofilm detection tools to facilitate biofilm visualization and
optimal wound management.
 Establishment of optimal techniques for identifying biofilms in recalcitrant
wounds and optimizing their predictive validity to inform clinical decisions.
 What sort of patient assessments or local wound therapies can reliably prevent
delayed healing or progression to infection associated with biofilm formation?
 How do biofilms interact with slough, necrotic tissue, sutures, or other
foreign bodies? Do they underlie or potentiate infection or protect from
host immune attack?
 Compare autolytic with other debridement methods in quality random-
ized clinical trials (RCTs) to strengthen evidence for debriding wound
biofilms and the compromised tissue on which they thrive.
 Compare methods of managing wound biofilms in RCTs to find which methods
have the greatest efficacy, safety, and cost effectiveness for managing biofilm.
 Continue to develop in vitro and in vivo wound biofilm models that reflect
the clinical situation in nonhealing wounds.
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help identify host and wound environmental fac-
tors that increase the predictive and diagnostic
validity of biofilms for early screening of patients at
risk of delayed healing or wound infection (Fig. 4).
The capacity of biofilm formation to predict delayed
healing may increase in subjects with conditions
such as impaired arterial or venous circulation or
diabetes. Wound surface biofilm may serve as an
early signal to alert clinicians that the wound has
diverted off its normal healing path before a re-
duced rate of wound contraction is noticed after 2–4
weeks of treatment. Figure 4 highlights interre-
lated variables that can be used as a guide to gen-
erate an effective approach to optimize screening
and diagnostic value of wound biofilm. Detection of
early (young) biofilmsmay identify at-risk patients
and enable intervention before recalcitrance and/
or infection become a problem.
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